Electronic cigarettes pose less danger than traditional smoking

Jul.08.2022
Electronic cigarettes pose less danger than traditional smoking
Evidence shows that vaping is less harmful than smoking and can help smokers quit, but media coverage has hindered public understanding.

The evidence is clear: vaping is less dangerous than smoking and can help many people quit their deadly smoking habit. No public data can refute these two conclusions, but tobacco control researchers, activists, and federal regulatory agencies often deny or downplay these observations. This contaminates the public's understanding of electronic cigarettes and prevents smokers from trying out alternative solutions that could potentially save their lives.


Using electronic cigarettes helped me successfully quit smoking, according to a recent conclusion published in the American Journal of Preventive Medicine. Medscape reported on June 20 that "an increasing number of American adults believe that electronic cigarettes are more harmful than traditional cigarettes.


Why are the public afraid of electronic cigarettes?


The author analyzed data collected as part of the Health Information National Trends Survey (HINTS), which is a nationally representative survey conducted through mail that asks American adults about their attitudes towards cancer and other health-related information. The data was collected over five cycles between January 2018 and May 2020, with over 3000 respondents included in the final analysis each year (3360 in 2018, 3217 in 2019, and 3677 in 2020). The author reports that...


The relative perceived harm of electronic cigarettes versus traditional cigarettes was assessed through the following question with six possible answers: Compared to smoking, would you say that electronic cigarettes are... Respondents were categorized as perceiving electronic cigarettes to be less harmful (less harmful or much less harmful) than traditional cigarettes, equally harmful, or more harmful (more harmful or much more harmful) than traditional cigarettes.


The author suggests that the negative shift in perception may have been driven by the media's coverage of the so-called "EVALI outbreak". From 2019 to 2020, over 2,000 individuals were hospitalized due to e-cigarette related lung injuries and 68 people died.


These cases were not caused by electronic cigarettes themselves, which were mistakenly maintained by the Centers for Disease Control and Prevention for a few months, but by devices purchased illegally for vaping THC or CBD. These chemicals, derived from cannabis rather than tobacco, were mixed with vitamin E acetate which may have contributed to the reported lung injuries. Dr. Josh Bloom provided a helpful explanation of the chemical reaction behind this phenomenon in the story, which subsequent research has confirmed.


During the outbreak of EVALI, journalists did what they often do without having all the facts: they amplified the risk, with the tacit approval of the Centers for Disease Control, but were not interested in reporting on the controversy surrounding the decision. According to the study authors:


In March and April of 2020, there was a high level of harmful relative opinions. This suggests that misunderstandings have persisted since the initial discovery of the connection to vitamin E acetate in September 2019, possibly due to media coverage not remaining at the same level after the source of the epidemic was determined.


The trend is still continuing.


EVALI is no longer a major public health concern, but controversial ideological radicalism and careless reporting continue to undermine electronic cigarettes as a harm reduction tool in today's society. Researchers have published low-quality studies alleging serious health consequences from using e-cigarettes, and the media dutifully reported on these findings. The ACSH and other scientifically-minded media outlets have corrected the propaganda, but unfortunately, this good news has not garnered as much attention as sensational and scary headlines.


Experts recognize the issue and acknowledge the need for a solution. According to a doctor, we are effective at communicating the harmful effects of smoking and the dangers of tobacco in public health. Ashley Brooks-Russell, associate professor at the Colorado School of Public Health, stated to Medscape Medical News that we struggle to discuss smaller choices, such as the lesser harm of e-cigarettes compared to smoking.


Dr. Russell is correct, but I will go even further. Even though researchers have documented the harm caused by common anti-vaping metaphors, tobacco researchers cannot abandon their skepticism of e-cigarettes. As the authors of the study themselves have written,


Electronic cigarettes contain high levels of nicotine and appealing flavors that may lead to addiction and the use of combustible tobacco products among adolescents and young adults.


The sentence is at least partially false. Many electronic cigarettes contain little to no nicotine. Flavored electronic cigarettes do not encourage youth to use any tobacco products, and there is no concrete evidence to support this speculation. The author also reiterated the anti-electronic cigarette stance, which has become a staunch article among tobacco researchers: "The risks associated with long-term use are still unclear." This is undoubtedly true, as no one has a crystal ball, but public health researchers often use such language to suggest that we will discover some serious risks associated with electronic cigarettes in the future.


The American Cancer Society claims that the long-term risks of only using electronic cigarettes are not yet fully clear. However, there is increasing evidence that using e-cigarettes has negative effects on the cardiovascular system and lungs. If immediate action is not taken to stop the widespread use of these products, the long-term adverse health effects will increase.


Can you imagine a large medical institution issuing a statement similar to this regarding the use of COVID-19 vaccines or puberty blockers for treating gender dysphoria? After all, we do not know the potential long-term effects of these powerful drugs on those who take them. Of course, until we have a better understanding of these products, we must halt their "popular use," shouldn't we?


If these issues are frustrating you, then maybe you're starting to understand why the popular rhetoric surrounding e-cigarettes is so absurd. Properly evaluating any product requires accurately balancing its risks and benefits. No one is claiming that e-cigarettes are risk-free; they are an effective intervention aimed at reducing the harm of smoking, which is killing people all over the world.


Given this standard, speculating about potential hazards we may discover one day is a foolish thought exercise. Let the public know what we know today: for adult smokers who want to quit smoking, electronic cigarettes are a low-risk option.


This article is compiled from third-party information and is only intended for educational purposes. The copyright of the compiled information belongs to the original media and authors. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Elf Bar Vape Explosion and Amputation Claim Spurs Coverage Suit, U.S. Insurer MUSIC Seeks Ruling It Owes No Duty to Defend or Indemnify Distributor i5
Elf Bar Vape Explosion and Amputation Claim Spurs Coverage Suit, U.S. Insurer MUSIC Seeks Ruling It Owes No Duty to Defend or Indemnify Distributor i5
Mesa Underwriters Specialty Insurance Company has asked a federal court in Washington to declare that it has no duty to defend or indemnify vape distributor i5 Distribution in a product liability case involving an Elf Bar BC5000. The plaintiff alleges that the disposable vape caught fire and exploded in his pocket, causing severe burns and ultimately requiring an above-the-knee amputation of his left leg. MUSIC is relying on a tobacco, nicotine or nicotine replacement products exclusion and a premises limitation endorsement. The court has not ruled on the coverage dispute.
News
Sep.10
Product | PIXL Adds 6ml PIXL 5K in UK Alongside 12ml PIXL 8000 as Vape Duty Takes Effect
Product | PIXL Adds 6ml PIXL 5K in UK Alongside 12ml PIXL 8000 as Vape Duty Takes Effect
Vaping brand PIXL has introduced the PIXL 5K reusable prefilled pod device in the UK, featuring a 2ml prefilled pod and a 4ml refill container with a combined e-liquid capacity of 6ml. The device uses 20mg/ml nicotine salt e-liquid and is advertised to deliver up to approximately 5,000 puffs. Available through UK retailers by August 2026, the PIXL 5K sits alongside the existing 12ml PIXL 8000. The UK's Vaping Products Duty took effect on October 1 at £0.22 per millilitre, producing theoretical duty amounts of £1.32 and £2.64 for the two products' respective full refill sets.
product
Oct.10
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
Less than a week after JUUL2 received U.S. FDA marketing authorization on August 28, 2026, JUUL Labs was sued for patent infringement in federal court in Delaware. AJ Marketing LLC filed the complaint on September 3, alleging that both JUUL 1 and JUUL2 infringe U.S. Patent No. 8,851,068 B2. The patent covers aspects of programmable electronic vaporization devices, including controls over dose delivery, usage frequency and operating parameters. The plaintiff is seeking reasonable royalties and ongoing royalties tied to the remaining life of the patent. JUUL has not yet publicly responded to the case.
Sep.10
IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech launched IKE 2.0 on September 28, initially targeting nicotine products with a platform that combines user identity verification, product authentication, configurable policy controls and data analytics. Products can be authenticated through direct device integration or NFC smart tags. IKE Tech was formed with participation from Ispire's Aspire North America, Berify and Chemular, with Ispire currently holding a 40% interest. Its age-verification component PMTA was accepted by the FDA in 2025 and remains under review. The company did not disclose customer names, commercial deployment volumes, pricing or revenue tied to IKE 2.0.
News
Sep.29 by 2Firsts Perspectives
PMI Launches Fourth IQOS Convenience-Store Discount of 2026 for Black Friday in Japan, Cutting ILUMA i ONE to About $19 After Ploom AURA Fell to About $9
PMI Launches Fourth IQOS Convenience-Store Discount of 2026 for Black Friday in Japan, Cutting ILUMA i ONE to About $19 After Ploom AURA Fell to About $9
Philip Morris Japan launched its fourth confirmed nationwide convenience-store discount campaign for IQOS ILUMA i devices in 2026 on October 26, cutting three models by as much as ¥2,000, or about $12.70. The campaign began one day after JT ended a promotion that reduced Ploom AURA to ¥1,480, or about $9.40. JT says Ploom's share of Japan's heated-products category rose from 10.9% in January 2024 to 18.3% in June 2026, a gain of 7.4 percentage points, while PMI says IQOS still held about 68% category share in the third quarter. At the same time, Japan's two-stage heated-tobacco tax adjustment has pushed stick prices higher, leaving device discounts as an increasingly important tool for lowering the upfront cost of customer acquisition.
Market
Oct.28
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07